drugset / Trial / NCT01609556
First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Mirvetuximab Soravtansine in Adults With Ovarian Cancer and Other Folate Receptor 1 (FOLR1)-Positive Solid Tumors
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to test mirvetuximab soravtansine (IMGN853) in participants with ovarian cancer and other FOLR-1 positive tumors.
Timeline
- Start
- 2012-06-28
- Primary completion
- 2018-03-19
- Completion
- 2018-03-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mirvetuximab Soravtansine | Other / unclassified | 0.15 mg/kg | Intravenous |
| Subject | Mirvetuximab Soravtansine | Other / unclassified | 1.1 mg/kg | Intravenous |
| Subject | Mirvetuximab Soravtansine | Other / unclassified | 2.5 mg/kg | Intravenous |
| Subject | Mirvetuximab Soravtansine | Other / unclassified | 6 mg/kg | Intravenous |
| Subject | Mirvetuximab Soravtansine | Other / unclassified | 7 mg/kg | Intravenous |